fda warning peptides bpc-157 safety unapproved drug peptide Committee Votes to Ease Restrictions on Six fda warning bpc-157 status not – fda warning bpc-157 peptide not

Upcoming Events August 5 1:00 pm to 2:00 pm ET Peptide Compounding on the Rise: Key Pharmacy Considerations Join APhA for a live webinar exploring non-FDA approved compounded peptides and key pharmacy considerations

When evaluating suppliers, researchers should look for third-party testing certificates showing purity of 98% or higher, clear documentation of the compound identity, established reputation in the research community, and responsive customer service that can answer technical questions

The legal access landscape shifted meaningfully in April 2026 when the FDA removed both peptides from its Category 2 restricted list

Since BPC-157 has not been thoroughly tested in humans, its safety profile remains unknown

Reference: Kaiqiang Sun, Jiuyi Sun, Chen Yan, et

Proper Documentation for CPT Code 20220 Accurate and thorough documentation is essential for preventing denials and for distinguishing CPT 20220 from other musculoskeletal biopsy codes